Roche has announced its acquisition of Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion. As part of the deal, Roche will have the rights to develop, manufacture, and commercialize RVT-3101, an experimental antibody, in the US and Japan. Roche described RVT-3101 as a "promising" therapy for inflammatory bowel disease, ulcerative colitis, and Crohn s disease.
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss pharmaceutical giant seeks to bolster its.
Roche To Pay $7 1 Bn For Telavant Holdings barrons.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from barrons.com Daily Mail and Mail on Sunday newspapers.
Roche to Buy Telavant from Roivant Sciences, Pfizer for $7 1 Billion barrons.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from barrons.com Daily Mail and Mail on Sunday newspapers.